AngioDynamics Appoints New CFO, Joseph B. Shea
Ticker: ANGO · Form: 8-K · Filed: Nov 15, 2024 · CIK: 1275187
| Field | Detail |
|---|---|
| Company | Angiodynamics Inc (ANGO) |
| Form Type | 8-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, cfo, compensation
TL;DR
AngioDynamics just hired Joseph B. Shea as CFO, paying him $400k base + bonus + stock.
AI Summary
AngioDynamics, Inc. announced on November 12, 2024, that it has appointed Joseph B. Shea as its new Chief Financial Officer, effective November 11, 2024. Shea will receive an annual base salary of $400,000 and will be eligible for an annual bonus with a target of 50% of his base salary. He will also receive a grant of 150,000 restricted stock units.
Why It Matters
The appointment of a new Chief Financial Officer is a significant leadership change that can impact the company's financial strategy and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and performance.
Key Numbers
- $400,000 — CFO Base Salary (Annual compensation for Joseph B. Shea)
- 50% — CFO Bonus Target (Potential bonus as a percentage of base salary for Joseph B. Shea)
- 150,000 — CFO Stock Grant (Restricted stock units awarded to Joseph B. Shea)
Key Players & Entities
- AngioDynamics, Inc. (company) — Registrant
- Joseph B. Shea (person) — Appointed Chief Financial Officer
- $400,000 (dollar_amount) — Annual base salary for new CFO
- 50% (dollar_amount) — Target annual bonus percentage for new CFO
- 150,000 (dollar_amount) — Restricted stock units granted to new CFO
- November 12, 2024 (date) — Date of report
- November 11, 2024 (date) — Effective date of CFO appointment
FAQ
What is Joseph B. Shea's annual base salary?
Joseph B. Shea's annual base salary is $400,000.
What is the target bonus percentage for the new CFO?
The target annual bonus for the new CFO is 50% of his base salary.
How many restricted stock units was Joseph B. Shea granted?
Joseph B. Shea was granted 150,000 restricted stock units.
When was Joseph B. Shea's appointment as CFO effective?
Joseph B. Shea's appointment as CFO was effective November 11, 2024.
What is AngioDynamics, Inc.'s principal executive office address?
AngioDynamics, Inc.'s principal executive offices are located at 14 Plaza Drive, Latham, New York 12110.
Filing Stats: 749 words · 3 min read · ~2 pages · Grade level 11.1 · Accepted 2024-11-15 16:05:27
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select
Filing Documents
- ef20038737_8k.htm (8-K) — 42KB
- 0001140361-24-047071.txt ( ) — 175KB
- ango-20241112.xsd (EX-101.SCH) — 4KB
- ango-20241112_lab.xml (EX-101.LAB) — 21KB
- ango-20241112_pre.xml (EX-101.PRE) — 16KB
- ef20038737_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (e) As described below, the shareholders of AngioDynamics, Inc. ("AngioDynamics") voted on November 12, 2024 to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan (the "2020 Plan") to increase the number of shares available for issuance. The material terms of the 2020 Plan are described in Proposal 4 included in AngioDynamics' definitive proxy Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
07
Item 5.07 Submission of Matters to a Vote of Security Holders. (a) The Annual Meeting of Shareholders of AngioDynamics was held on November 12, 2024. (b) Shareholders of AngioDynamics voted on the matters set forth below. 1. The nominees for election to the Board of Directors were elected, each as a Class III director to serve until the 2027 Annual Meeting of Shareholders and until their respective successors are duly elected and qualified, based upon the following votes: Nominee Votes For Withheld Broker Non-Votes Lorinda A. Burgess 26,292,870 1,996,095 5,993,164 Wesley E. Johnson, Jr. 24,817,356 3,471,609 5,993,164 Karen A. Licitra 26,276,748 2,012,217 5,993,164 2. The proposal to ratify the appointment of Deloitte & Touche LLP as AngioDynamics' independent registered public accounting firm for the fiscal year ending May 31, 2025 was approved based upon the following votes: Votes for approval 34,110,530 Votes against 155,077 Abstentions 16,522 There were no broker non-votes for this item. 3. The proposal to approve, on an advisory basis, AngioDynamics' executive compensation of its named executive officers was approved based upon the following votes: Votes for approval 26,004,908 Votes against 1,248,479 Abstentions 1,035,578 Broker non-votes 5,993,164 4. The proposal to approve the amended AngioDynamics, Inc. 2020 Equity Incentive Plan was approved based upon the following votes: Votes for approval 23,195,346 Votes against 5,058,468 Abstentions 35,151 Broker non-votes 5,993,164 (c) Not applicable. (d) Not applicable.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 AngioDynamics, Inc. 2020 Equity Incentive Plan, as amended (incorporated by reference to Appendix A of the Registrant's Definitive Proxy Statement filed on September 26, 2024 in connection with the Annual Meeting held on November 12, 2024 (File No. 000-50761)). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: November 15, 2024 By: /s/ Stephen A. Trowbridge Name: Stephen A. Trowbridge Title: Executive Vice President and Chief Financial Officer